- Home
- WNEB vs AARD Comparison
WNEB vs AARD Comparison
Compare WNEB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- AARD
- Stock Information
- Founded
- WNEB 1853
- AARD 2017
- Country
- WNEB United States
- AARD United States
- Employees
- WNEB N/A
- AARD N/A
- Industry
- WNEB Savings Institutions
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- WNEB Finance
- AARD Health Care
- Exchange
- WNEB Nasdaq
- AARD Nasdaq
- Market Cap
- WNEB 195.7M
- AARD 231.9M
- IPO Year
- WNEB N/A
- AARD 2025
- Fundamental
- Price
- WNEB $11.82
- AARD $10.68
- Analyst Decision
- WNEB Buy
- AARD Strong Buy
- Analyst Count
- WNEB 2
- AARD 8
- Target Price
- WNEB $11.00
- AARD $30.75
- AVG Volume (30 Days)
- WNEB 39.0K
- AARD 169.6K
- Earning Date
- WNEB 10-28-2025
- AARD 11-13-2025
- Dividend Yield
- WNEB 2.36%
- AARD N/A
- EPS Growth
- WNEB 27.15
- AARD N/A
- EPS
- WNEB 0.66
- AARD N/A
- Revenue
- WNEB $79,080,000.00
- AARD N/A
- Revenue This Year
- WNEB N/A
- AARD N/A
- Revenue Next Year
- WNEB $7.48
- AARD N/A
- P/E Ratio
- WNEB $18.07
- AARD N/A
- Revenue Growth
- WNEB 9.08
- AARD N/A
- 52 Week Low
- WNEB $7.63
- AARD $4.88
- 52 Week High
- WNEB $12.80
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- WNEB 61.17
- AARD 43.28
- Support Level
- WNEB $11.65
- AARD $9.34
- Resistance Level
- WNEB $11.93
- AARD $10.94
- Average True Range (ATR)
- WNEB 0.27
- AARD 0.79
- MACD
- WNEB 0.09
- AARD -0.10
- Stochastic Oscillator
- WNEB 95.40
- AARD 46.99
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.